Evoltra: Withdrawal of the application to change the marketing authorisation
On 18 March 2008, Bioenvision Ltd, a wholly owned subsidiary of Genzyme Corporation, officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a change to the marketing authorisation for Evoltra. The change concerned an extension of indication to add the treatment of acute myeloid leukaemia in elderly patients. Evoltra was designated as an orphan medicine for this condition on 8 May 2003.
|Date of issue of market authorisation valid throughout the European Union (if applicable)||
|International non-proprietary name (INN) or common name||
|Date of withdrawal||
|Company making the application|
Withdrawal assessment report for Evoltra (PDF/156.56 KB)Adopted
First published: 09/04/2008
Last updated: 09/04/2008
Bioenvision Ltd withdraws its application for an extension of indication for Evoltra (clofarabine) (PDF/19.02 KB)
First published: 19/03/2008
Last updated: 19/03/2008
Questions and answers on the withdrawal of a change to the marketing authorisation for Evoltra (PDF/36.91 KB)
First published: 24/04/2008
Last updated: 24/04/2008
Related information on withdrawals
The question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the application at the time of the withdrawal, and includes a link to the company's formal withdrawal letter.
An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 90').